Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00338741 · ClinicalTrials.gov registry record
Rebif® Pregnancy Registry
A clinical trial, sponsored by EMD Serono.
- Completed
- Registry status
- 36
- Enrollment target
NCT00338741 is a clinical trial that has completed, run by EMD Serono. The registered enrollment target is 36 participants.
The verdict
NCT00338741 has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- 36 participants
- Enrollment target
Study Summary
The objective for establishing the Rebif® Pregnancy Registry is to collect prospective outcomes data on women in the United States and Canada who have been exposed to Rebif® during their pregnancies. The primary end point will be the rate of spontaneous abortions in exposed pregnancies. This rate will be compared with the rate of spontaneous abortions in patients with Multiple Sclerosis (MS) whose pregnancies were not exposed to any interferon-beta in a manner consistent with the FDA August 2002 Guidance for Industry: Establishing Pregnancy Exposure Registries
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2002-12 |
| Est. Completion | 2008-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00338741
The ClinicalTrials.gov registry entry for NCT00338741 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00338741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00338741 about?
NCT00338741 is a clinical study titled "Rebif® Pregnancy Registry". The objective for establishing the Rebif® Pregnancy Registry is to collect prospective outcomes data on women in the United States and Canada who have been exposed to Rebif® during their pregnancies. The primary end point will be the rate of spontaneous abortions in exposed pregnancies. This rate wi...
What is the current status of trial NCT00338741?
This trial is currently completed. The enrollment target is 36 participants. The study started on 2002-12. Estimated completion is 2008-02.
Who is sponsoring clinical trial NCT00338741?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.